Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
arö
https://www.helmholtz-berlin.de/pubbin/news_seite?nid=28606;sprache=en
- Copy link
-
New method shows how molecular switches are influenced by their neighbors
Researchers at Friedrich Schiller University Jena and the Helmholtz Centre Berlin (HZB) have, for the first time, been able to directly observe how the environment surrounding a molecular switch influences its electronic structure. Molecular switches are molecules that can be switched between two states by external influences such as changes in temperature—similar to a switch with the positions »On« and »Off«. Such molecules are being investigated as potential building blocks for future data storage devices or sensor materials. Using magnetic-field-dependent terahertz spectroscopy, the researchers have now, for the first time, been able to distinguish whether neighbouring molecules in a material are in the same or different states. The results have been published in the journal »Angewandte Chemie International Edition«.
-
SEAlab accelerator project completed: Achievements and outlook
The SEAlab accelerator project successfully completed its final measurement campaign in summer 2026. The facility is now being dismantled, with many components set to be reused. The two accelerator physicists, Axel Neumann and Thorsten Kamps, explain what the project has achieved and provide an outlook for the future.
-
BESSY II is back in operation after maintenance shutdown
On 7 September 2026, BESSY II was set into operation after a four-week shutdown. BESSY II is scheduled to resume full user operation on 22 September.